Abstract: ObjectiveTo observe the influence of conventional chemotherapy drugs combined with epidermal growth factor receptor (EGFR) targeted drug C225 and human epidermal growth factor receptor-2 (HER2) targeted drug trastuzumab on proliferation of squamous cell carcinoma of the esophagus HE-2 cell line.MethodsMethyl thiazolyl tetrazolium bromide (MTT) assay and flow cytometry were applied to detect the effects of fluorourcil (5-FU) combined with C225 or 5-FU combined with trastuzumab on the proliferation of HE-2 cells.ResultsThe in vitro experiments showed that after the treatments of 5-Fu combined with C225 for 24 hours and 48 hours,the inhibition rate of HE-2 cell proliferation was 45.29±0.16 and 70.63±0.10,significantly higher than those of 5-Fu combined with trastuzumab(33.02±0.19 and 50.08±0.20) (P<0.05 for all).With the treatment of 5-Fu combined with C225 for 24 hours and 48 hours,the apoposis rate of HE-2 cells was 15.47±1.62% and 26.89±1.12%,significantly higher than those of treatment of 5-FU combined with trastuzumab (7.34±0.88% and 15.56±0.97%) (P <0.05 for all).ConclusionThe targeted drug C225 combined with 5-FU for EGFR pathway shows a synergistic effect on inhibition of the proliferation in HE-2 cells and the signal pathway of EGFR could be as a target for the treatment of human esophageal carcinoma.